- Home
- HNGE vs PTGX Comparison
HNGE vs PTGX Comparison
Compare HNGE & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HNGE
- PTGX
- Stock Information
- Founded
- HNGE 2012
- PTGX 2006
- Country
- HNGE United States
- PTGX United States
- Employees
- HNGE N/A
- PTGX N/A
- Industry
- HNGE
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- HNGE
- PTGX Health Care
- Exchange
- HNGE NYSE
- PTGX Nasdaq
- Market Cap
- HNGE 2.8B
- PTGX 3.3B
- IPO Year
- HNGE 2025
- PTGX 2016
- Fundamental
- Price
- HNGE $44.95
- PTGX $53.83
- Analyst Decision
- HNGE Strong Buy
- PTGX Strong Buy
- Analyst Count
- HNGE 13
- PTGX 9
- Target Price
- HNGE $49.17
- PTGX $67.11
- AVG Volume (30 Days)
- HNGE 588.8K
- PTGX 637.6K
- Earning Date
- HNGE 08-05-2025
- PTGX 08-05-2025
- Dividend Yield
- HNGE N/A
- PTGX N/A
- EPS Growth
- HNGE N/A
- PTGX N/A
- EPS
- HNGE 4.07
- PTGX 0.86
- Revenue
- HNGE $431,521,000.00
- PTGX $207,801,000.00
- Revenue This Year
- HNGE $33.58
- PTGX N/A
- Revenue Next Year
- HNGE $19.85
- PTGX $53.09
- P/E Ratio
- HNGE $11.03
- PTGX $62.41
- Revenue Growth
- HNGE 33.37
- PTGX N/A
- 52 Week Low
- HNGE $33.42
- PTGX $32.50
- 52 Week High
- HNGE $52.16
- PTGX $60.60
- Technical
- Relative Strength Index (RSI)
- HNGE N/A
- PTGX 49.46
- Support Level
- HNGE N/A
- PTGX $53.06
- Resistance Level
- HNGE N/A
- PTGX $57.15
- Average True Range (ATR)
- HNGE 0.00
- PTGX 1.76
- MACD
- HNGE 0.00
- PTGX -0.22
- Stochastic Oscillator
- HNGE 0.00
- PTGX 36.89
About HNGE HINGE HEALTH INC
Hinge Health Inc is a technology platform for individuals seeking to treat and prevent joint and muscle pain. Through a combination of AI-powered motion tracking technology, the Company's platform helps members address musculoskeletal (MSK) conditions, enables improved member outcomes and supports cost reductions for its clients. The Company's clients are self-insured employers.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.